However, when cervical cancer cells are stimulated with high doses of IL-2 and subsequently with anti-CD95 agonist antibodies at a concentration that induces proliferation, we observed that proliferation is recovered (Figure 3E,F), that is, the inhibition induced by IL-2 is lost. Here, IL2 is linked to cervical carcinoma.